why does tirzepatide cause pancreatitis Mounjaro 2026: 0.3% Risk + Prior History Guide Tirzepatide and Pancreatitis Risk: Safe

A March 2024 study conducted in France identified a 5.55-fold increased risk of meningioma among women who used Depo-Provera for one year or longer

These early insights from the COURAGE trial are consistent with recently published pre-clinical data in rodents and non-human primates, and clearly establish the principle that blocking GDF8 with or without activin A can preserve muscle and further increase fat loss in patients being treated with GLP-1 therapy, thereby improving the quality of weight loss

[DOI] [PubMed] [Google Scholar] 6.Ludvik B., Giorgino F., Jdar E., et al

Furthermore, GLP-1 RAs have demonstrated benefits beyond glucose regulation, including positive effects on cardiovascular health

Because Ozempic and Mounjaro contain different active ingredients, their dosage schedules differ even though they are both injected once weekly